Short-term effect of the New Nordic Renal Diet on phosphorus homoeostasis in chronic kidney disease Stages 3 and 4

被引:12
|
作者
Salomo, Louise [1 ,2 ]
Rix, Marianne [1 ]
Kamper, Anne-Lise [1 ]
Thomassen, Jesper Q. [3 ]
Sloth, Jens J. [4 ]
Astrup, Arne [2 ]
机构
[1] Rigshosp, Univ Hosp Copenhagen, Dept Nephrol, Copenhagen, Denmark
[2] Univ Copenhagen, Fac Sci, Dept Nutr Exercise & Sports, Copenhagen, Denmark
[3] Rigshosp, Univ Hosp Copenhagen, Dept Clin Biochem, Copenhagen, Denmark
[4] Tech Univ Denmark, Natl Food Inst, Kemitorvet, Denmark
关键词
24-h urine phosphorus excretion; chronic kidney disease (CKD); dietary intervention; fibroblast growth factor 23 (FGF23); New Nordic Renal Diet (NNRD); GROWTH-FACTOR; 23; MEDITERRANEAN DIET; PHOSPHATE INTAKE; CLINICAL-TRIAL; CKD PATIENTS; CALCIUM; MORTALITY; FGF-23; RISK; HYPERTENSION;
D O I
10.1093/ndt/gfy366
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. The New Nordic Diet is a food concept favouring organically produced food items, fruits, vegetables, whole grains and fish. We investigated the short-term effects of a modified phosphorus-reduced New Nordic Renal Diet (NNRD) in chronic kidney disease (CKD) patients on important parameters of phosphorus homoeostasis. Methods. The NNRD contained a total of 850 mg phosphorus/day. A total of 18 patients, CKD Stages 3 and 4 were studied in a randomized crossover trial comparing a 1-week control period of the habitual diet with a 1-week period of the NNRD. Data were obtained at baseline and during 1 week of dietary intervention (habitual diet versus NNRD) by collecting fasting blood samples and 24-h urine collections. The primary outcome was the difference in the change in 24-h urine phosphorus excretion from baseline to Day 7 between the NNRD and habitual diet periods. Secondary outcomes were changes in the fractional excretion of phosphorus, fibroblast growth factor 23 (FGF23) and plasma phosphate. Results. As compared with the habitual diet, 24-h urine phosphorus excretion was reduced in the NNRD by 313 mg/day (P < 0.001). The mean baseline phosphorus was 875 +/- 346 mg/day and was decreased by 400 +/- 256 mg/day in the NNRD and 87 +/- 266 mg/day in the habitual diet. The 24-h urine fractional excretion of phosphorus decreased by 11% (P < 0.001) and FGF23 decreased by 30 pg/mL (P = 0.03) with the NNRD compared with the habitual diet. Plasma phosphate did not change. Conclusion. This study demonstrates that dietary phosphorus restriction in the context of the NNRD is feasible and has positive effects on phosphorus homeostasis in CKD patients.
引用
收藏
页码:1691 / 1699
页数:9
相关论文
共 50 条
  • [21] Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality
    McCullough, Peter A.
    Li, Suying
    Jurkovitz, Claudine T.
    Stevens, Leslie
    Collins, Alan J.
    Chen, Shu-Cheng
    Norris, Keith C.
    McFarlane, Samy
    Johnson, Bruce
    Shlipak, Michael G.
    Obialo, Chamberlain I.
    Brown, Wendy W.
    Vassaloti, Joseph
    Whaley-Connell, Adam T.
    Brenner, Robert M.
    Bakris, George L.
    AMERICAN HEART JOURNAL, 2008, 156 (02) : 277 - 283
  • [22] Short-term effects of a very-low-protein diet supplemented with ketoacids in nondialyzed chronic kidney disease patients
    S F Feiten
    S A Draibe
    R Watanabe
    M R Duenhas
    A C Baxmann
    F B Nerbass
    L Cuppari
    European Journal of Clinical Nutrition, 2005, 59 : 129 - 136
  • [23] Short-term effects of a very-low-protein diet supplemented with ketoacids in nondialyzed chronic kidney disease patients
    Feiten, SF
    Draibe, SA
    Watanabe, R
    Duenhas, MR
    Baxmann, AC
    Nerbass, FB
    Cuppari, L
    EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2005, 59 (01) : 129 - 136
  • [24] EFFECTS OF SHORT-TERM POTASSIUM CHLORIDE SUPPLEMENTATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE
    Gritter, Martin
    Wouda, Rosa
    Yeung, Stanley Ming Hol
    Vogt, Liffert
    De Borst, Martin
    Rotmans, Joris
    Hoorn, Ewout
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36 : 285 - 285
  • [25] Short-Term Effects of NO2 Exposure on Hospitalization for Chronic Kidney Disease
    Zhang, Wancheng
    Ruan, Ye
    Ling, Jianglong
    TOXICS, 2024, 12 (12)
  • [26] Sclerostin as a new key factor in vascular calcification in chronic kidney disease stages 3 and 4
    Wei Lv
    Lina Guan
    Yan Zhang
    Shengqiang Yu
    Bofeng Cao
    Yongqiang Ji
    International Urology and Nephrology, 2016, 48 : 2043 - 2050
  • [27] Sclerostin as a new key factor in vascular calcification in chronic kidney disease stages 3 and 4
    Lv, Wei
    Guan, Lina
    Zhang, Yan
    Yu, Shengqiang
    Cao, Bofeng
    Ji, Yongqiang
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2016, 48 (12) : 2043 - 2050
  • [28] Role of Bone Biopsy in Stages 3 to 4 Chronic Kidney Disease
    Gal-Moscovici, Anca
    Sprague, Stuart M.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 : S170 - S174
  • [29] PREVALENCE OF CHRONIC KIDNEY DISEASE, STAGES 3, 4 AND 5 IN ADULTS
    Rodrigues Bastos, Rita Maria
    Bastos, Marcus Gomes
    Ribeiro, Luis Claudio
    Bastos, Ricardo Villela
    Bustamante Teixeira, Maria Teresa
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2009, 55 (01): : 40 - 44
  • [30] Asymmetric Dimethylarginine and Mortality in Stages 3 to 4 Chronic Kidney Disease
    Young, Jill Melendez
    Terrin, Norma
    Wang, Xuelei
    Greene, Tom
    Beck, Gerald J.
    Kusek, John W.
    Collins, Allan J.
    Sarnak, Mark J.
    Menon, Vandana
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 4 (06): : 1115 - 1120